Capital Fund Management S.A. Acquires 223,574 Shares of Tandem Diabetes Care, Inc. $TNDM
Capital Fund Management S.A. increased its holdings in Tandem Diabetes Care, Inc. by 575.4% in Q2, acquiring 223,574 shares. The fund now owns 262,431 shares worth $4.89 million. Other institutional investors also modified their holdings. Tandem Diabetes Care's stock opened at $20.51, with a market cap of $1.39 billion. The company reported Q3 earnings of ($0.31) per share and revenue of $249.25 million. Analysts have mixed ratings on the stock, with a consensus rating of 'Hold' and a price target of $21.25.
Capital Fund Management S.A. raised its holdings in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Free Report) by 575.4% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 262,431 shares of the medical device company's stock after buying an additional 223,574 shares during the quarter. Capital Fund Management S.A. owned about 0.39% of Tandem Diabetes Care worth $4,892,000 as of its most recent SEC filing.
Get Tandem Diabetes Care alerts:
Several other hedge funds and other institutional investors have also modified their holdings of TNDM. Russell Investments Group Ltd. raised its stake in Tandem Diabetes Care by 42.9% during the 2nd quarter. Russell Investments Group Ltd. now owns 198,713 shares of the medical device company's stock valued at $3,704,000 after purchasing an additional 59,619 shares during the last quarter. Advisors Asset Management Inc. increased its holdings in shares of Tandem Diabetes Care by 11.3% during the 2nd quarter. Advisors Asset Management Inc. now owns 25,001 shares of the medical device company's stock worth $466,000 after purchasing an additional 2,541 shares during the period. XTX Topco Ltd acquired a new position in shares of Tandem Diabetes Care during the second quarter valued at about $350,000. Edmond DE Rothschild Holding S.A. lifted its stake in shares of Tandem Diabetes Care by 4.0% in the second quarter. Edmond DE Rothschild Holding S.A. now owns 262,600 shares of the medical device company's stock valued at $4,895,000 after buying an additional 10,000 shares during the period. Finally, Champlain Investment Partners LLC grew its position in Tandem Diabetes Care by 6.3% during the second quarter. Champlain Investment Partners LLC now owns 1,455,123 shares of the medical device company's stock worth $27,123,000 after buying an additional 86,235 shares in the last quarter.
Tandem Diabetes Care Stock Down 2.4%
Shares of NASDAQ TNDM opened at $20.51 on Tuesday. The stock has a market cap of $1.39 billion, a PE ratio of -6.72 and a beta of 1.68. The business has a fifty day moving average of $15.89 and a two-hundred day moving average of $16.06. Tandem Diabetes Care, Inc. has a 52-week low of $9.98 and a 52-week high of $38.28. The company has a debt-to-equity ratio of 2.33, a quick ratio of 1.90 and a current ratio of 2.44.
Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) last posted its earnings results on Thursday, November 6th. The medical device company reported ($0.31) earnings per share for the quarter, hitting the consensus estimate of ($0.31). The business had revenue of $249.25 million for the quarter, compared to analyst estimates of $235.80 million. Tandem Diabetes Care had a negative net margin of 20.19% and a negative return on equity of 73.97%. The firm's quarterly revenue was up 2.2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.35) EPS. Tandem Diabetes Care has set its FY 2025 guidance at EPS. As a group, equities research analysts expect that Tandem Diabetes Care, Inc. will post -1.68 earnings per share for the current fiscal year.
Analysts Set New Price Targets
TNDM has been the subject of several recent research reports. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Tandem Diabetes Care in a report on Wednesday, October 8th. Wells Fargo & Company upped their target price on Tandem Diabetes Care from $13.00 to $14.00 and gave the company an "equal weight" rating in a research note on Friday, November 7th. Canaccord Genuity Group reaffirmed a "buy" rating and issued a $24.00 target price on shares of Tandem Diabetes Care in a research report on Monday, September 29th. Wall Street Zen raised shares of Tandem Diabetes Care from a "sell" rating to a "hold" rating in a report on Saturday, November 8th. Finally, Piper Sandler cut shares of Tandem Diabetes Care from an "overweight" rating to a "neutral" rating and dropped their price objective for the company from $30.00 to $14.00 in a research note on Thursday, August 7th. Four equities research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, Tandem Diabetes Care currently has a consensus rating of "Hold" and a consensus price target of $21.25.
Get Our Latest Research Report on TNDM
Tandem Diabetes Care Profile
(Free Report)Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.
See Also
- Five stocks we like better than Tandem Diabetes Care
- What is a Stock Market Index and How Do You Use Them?
- Up Over 20% in 2025, These 3 Stocks Are Boosting Buyback Capacity
- What is the Dogs of the Dow Strategy? Overview and Examples
- Congress Beat the Market Again—Here Are the 3 Stocks They Bought
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- Go on a Shopping Spree With 3 Top Retail ETFs
Want to see what other hedge funds are holding TNDM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in Tandem Diabetes Care Right Now?
Before you consider Tandem Diabetes Care, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tandem Diabetes Care wasn't on the list.
While Tandem Diabetes Care currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
